Actos

[Pioglitazone]

Indications & Dosage
INDICATIONS AND USAGE

ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM). ACTOS is indicated for monotherapy. ACTOS is also indicated for use in combination with a sulfonyl-urea, metformin, or insulin when diet and exercise plus the single agent does not result in adequate glycemic control.

Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise. These efforts are important not only in the primary treatment of type 2 diabetes, but also to maintain the efficacy of drug therapy.

Text Continues Below

---

DOSAGE AND ADMINISTRATION

ACTOS should be taken once daily without regard to meals.
The management of antidiabetic therapy should be individualized. Ideally, the response to therapy should be evaluated using HbA1c which is a better indicator of long-term glycemic control than FBG alone. HbA1c reflects glycemia over the past two to three months. In clin-ical use, it is recommended that patients be treated with ACTOS for a period of time ade-quate to evaluate change in HbA1c (three months) unless glycemic control deteriorates.

Monotherapy

ACTOS monotherapy in patients not adequately controlled with diet and exercise may be ini-tiated at 15 mg or 30 mg once daily. For patients who respond inadequately to the initial dose of ACTOS, the dose can be increased in increments up to 45 mg once daily. For patients not responding adequately to monotherapy, combination therapy should be considered.

Combination Therapy Sulfonylureas:

ACTOS in combination with a sulfonylurea may be initiated at 15 mg or 30 mg once daily. The current sulfonylurea dose can be continued upon initiation of ACTOS therapy. If patients report hypoglycemia, the dose of the sulfonylurea should be decreased.

Page:  1 | 2 | 3 | Next >>